Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.58 |
| ▸ | HTR2A | P28223 | 4/20 | 0.58 |
| ▸ | HTR2C | P28335 | 4/20 | 0.58 |
| ▸ | HTR2B | P41595 | 4/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CCR5 | P51681 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339985 | 1.00 | SIGMAR1 (0.58) | SIGMAR1HTR2AHTR2CHTR2BCHRM2 | |
| SCHEMBL4220408 | 0.82 | OPRM1 (0.63) | SIGMAR1HTR2ACHRM2CHRM3OPRM1 | |
| Hydrochloric Acid SCHEMBL4920052 | 0.81 | OPRM1 (0.62) | SIGMAR1HTR2ACHRM2CHRM3OPRM1 | |
| SCHEMBL5862792 | 0.81 | KCNH2 (0.72) | SIGMAR1CHRM2CHRM3ACHECCR5 | |
| Oxalic Acid SCHEMBL4217435 | 0.80 | OPRM1 (0.61) | SIGMAR1HTR2ACHRM2CHRM3OPRM1 | |
| SCHEMBL339807 | 0.77 | HTR2A (0.61) | SIGMAR1HTR2ACHRM2CHRM3OPRM1 | |
| SCHEMBL342820 | 0.76 | OPRM1 (0.59) | SIGMAR1HTR2ACHRM2CHRM3OPRM1 | |
| SCHEMBL22426263 | 0.76 | OPRM1 (0.59) | SIGMAR1HTR2ACHRM2CHRM3OPRM1 | |
| SCHEMBL5083771 | 0.76 | OPRM1 (0.69) | SIGMAR1HTR2ACHRM2CHRM3OPRM1 | |
| SCHEMBL9995041 | 0.76 | OPRM1 (0.55) | SIGMAR1HTR2ACHRM2CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1787984-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2016-10-19 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| EP-1787984-A2 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Arcadia Pharmaceuticals Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1263729-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | claimed |
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | claimed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | claimed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | claimed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | claimed |
| EP-1787984-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARM INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9296694-B2 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARMACEUTICALS INC. | 2015-09-17 | — | — | US | disclosed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | disclosed |
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | disclosed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | disclosed |
| US-6756393-B2 | AMIDES AND UREAS N-SUBSTITUTED WITH PIPERIDINE OR NORTROPANE; SEROTONIN INVERSE AGONISTS OR ANTAGONISTS; ANTIPSYCHOTIC | ACADIA PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | SIGMAR1 295/4885HTR2A 10/4885HTR2C 7/4885 |
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | SIGMAR1 295/4885HTR2A 10/4885HTR2C 7/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | SIGMAR1 295/4885HTR2A 10/4885HTR2C 7/4885 |
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | SIGMAR1 295/4885HTR2A 10/4885HTR2C 7/4885 |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | SIGMAR1 295/4885HTR2A 10/4885HTR2C 7/4885 |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | HTR2A, HTR1A, HTR1B | SIGMAR1 125/4885HTR2A 1/4885HTR2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.